Prescribing Psychiatric Drugs: The AI Frontier and its Risks
The Verge piece on AI-driven prescribing signals a troubling yet inevitable trend: as clinicians face shortages and patients seek faster access, AI-enabled tools are positioned to reshape clinical workflows. This development raises urgent questions about safety, transparency, and accountability. How will AI systems justify dosing decisions, monitor adverse effects, and coordinate with physicians who retain ultimate clinical responsibility? In practice, providers will need robust audit trails, explainability for patient-facing recommendations, and tight governance around data inputs and consent.
From a patient-safety perspective, the cost of misdiagnosis or dosage errors could be high. Industry stakeholders must invest in rigorous validation studies, post-market surveillance, and human-in-the-loop safeguards that empower clinicians to override AI recommendations when warranted. Conversely, proponents argue AI could reduce wait times and support clinical decision-making, especially in under-resourced settings. The balancing act for health systems will be to design deployment models that preserve clinician authority, ensure patient safety, and maintain trust with patients who rely on AI for sensitive health decisions. The broader takeaway is that as AI-enabled care expands, governance and oversight cannot be an afterthought; they must be embedded into the fabric of AI-enabled care pathways from design through deployment and ongoing monitoring.